Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (539)	2/23/1998 8:18:00 PM
From: BigKNY3	Read Replies (3) \| Respond to of 9523

Tonight's Big Pharma News: -Big Pharma hit an all-time high -PFE sets an all-time high 89 3/8 (+2 1/16) -MRK received approval of Singulair and jumped +6 3/16 -LLY continues to rebound to 64 7/8 (+3 1/4) - GLX and SBH break off merger talks. -Did you catch this DMG discussion in Barrons The 1990s have belonged to financial stocks and technology, which both have doubled their weightings in the S&P. "In recent decades, the market landscape has changed and a new market leader has emerged," says Tom Galvin, strategist at Deutsche Morgan Grenfell. "As we approach the millennium, people should be asking themselves what the new leader will be." Galvin is betting the next decade belongs to health-care stocks. His view: Drug companies and other health-care providers will generate consistently strong revenue and profit earnings at a time when other industries may falter. He points out that even with the sharp rise in drug stocks in 1997, the weighting of health-care stocks in the S&P is no higher than it was in 1991. Galvin believes busted health-care stocks like HMOs will revive as pricing improves, and he thinks favorable demographics will drive the major drug makers. "Operating leverage should increase at a time when S&P 500 margins could be on the downswing." Have PFun! BigKNY3